Literature DB >> 15380141

The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology.

Adam Balen1.   

Abstract

The pathophysiology of the polycystic ovary syndrome (PCOS) encompasses inherent ovarian dysfunction that is strongly influenced by external factors, such as disturbances of the hypothalamic-pituitary-ovarian axis and hyperinsulinaemia. Exaggerated gonadotrophin releasing hormone (GnRH) pulsatility results in hypersecretion of luteinising hormone (LH), which has effects both on ovarian androgen production and oocyte development. Disturbed ovarian-pituitary and hypothalamic feedback accentuates the 0gonadotrophin abnormalities. Hyperinsulinaemia is secondary both to insulin resistance at the periphery and to abnormal pancreatic beta cell function. PCOS runs in families and a number of genetic abnormalities appear to result in features of the syndrome and account for the heterogeneity of the symptoms. Environmental influences, such as nutrition and lifestyle, further influence expression of the syndrome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15380141     DOI: 10.1016/j.bpobgyn.2004.05.004

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  27 in total

1.  Metabolic Evidence of Diminished Lipid Oxidation in Women With Polycystic Ovary Syndrome.

Authors:  Leah D Whigham; Daniel E Butz; Hesam Dashti; Marco Tonelli; Luann K Johnson; Mark E Cook; Warren P Porter; Hamid R Eghbalnia; John L Markley; Steven R Lindheim; Dale A Schoeller; David H Abbott; Fariba M Assadi-Porter
Journal:  Curr Metabolomics       Date:  2014

Review 2.  Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome.

Authors:  Leopoldo O Tso; Michael F Costello; Luiz Eduardo T Albuquerque; Régis B Andriolo; Cristiane R Macedo
Journal:  Cochrane Database Syst Rev       Date:  2014-11-18

3.  Impact of Bariatric Surgery on Female Reproductive Health and Maternal Outcomes.

Authors:  S Christinajoice; Shivanshu Misra; Siddhartha Bhattacharya; S Saravana Kumar; B Deepa Nandhini; C Palanivelu; P Praveen Raj
Journal:  Obes Surg       Date:  2020-02       Impact factor: 4.129

4.  Dietary underreporting in women affected by polycystic ovary syndrome: A pilot study.

Authors:  Rachele De Giuseppe; Valentina Braschi; David Bosoni; Ginevra Biino; Fatima C Stanford; Rossella E Nappi; Hellas Cena
Journal:  Nutr Diet       Date:  2018-08-05       Impact factor: 2.333

5.  The effect of resistant dextrin as a prebiotic on metabolic parameters and androgen level in women with polycystic ovarian syndrome: a randomized, triple-blind, controlled, clinical trial.

Authors:  Sevda Gholizadeh Shamasbi; Parvin Dehgan; Sakineh Mohammad-Alizadeh Charandabi; Akbar Aliasgarzadeh; Mojgan Mirghafourvand
Journal:  Eur J Nutr       Date:  2018-02-26       Impact factor: 5.614

6.  Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome.

Authors:  Leopoldo O Tso; Michael F Costello; Luiz Eduardo T Albuquerque; Regis B Andriolo; Cristiane R Macedo
Journal:  Cochrane Database Syst Rev       Date:  2020-12-21

Review 7.  The role of steroids in follicular growth.

Authors:  Ann E Drummond
Journal:  Reprod Biol Endocrinol       Date:  2006-04-10       Impact factor: 5.211

8.  Relative importance of AMH and androgens changes with aging among non-obese women with polycystic ovary syndrome.

Authors:  Vitaly A Kushnir; Noy Halevy; David H Barad; David F Albertini; Norbert Gleicher
Journal:  J Ovarian Res       Date:  2015-07-09       Impact factor: 4.234

9.  N6-methyladenosine Demethylase FTO Induces the Dysfunctions of Ovarian Granulosa Cells by Upregulating Flotillin 2.

Authors:  Li Zhou; Xiao Han; Wei Li; Ning Wang; Lan Yao; Yunhe Zhao; Liqun Zhang
Journal:  Reprod Sci       Date:  2021-07-12       Impact factor: 3.060

10.  Weight loss for women with and without polycystic ovary syndrome following a very low-calorie diet in a community-based setting with trained facilitators for 12 weeks.

Authors:  Efsevia A Nikokavoura; Kelly L Johnston; John Broom; Wendy L Wrieden; Catherine Rolland
Journal:  Diabetes Metab Syndr Obes       Date:  2015-10-14       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.